{"name":"Sunesis Pharmaceuticals","slug":"sunesis-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SNS-032 Injection","genericName":"SNS-032 Injection","slug":"sns-032-injection","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"SNS-032 Injection","genericName":"SNS-032 Injection","slug":"sns-032-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPV28tNFZLRFA1alY4TUNhQU10TlVwTWw1S2RfbVBpQVhMUU02QmRBT0ZnM2NvSTRJQmNXb0xxaDFWYzlhUEQyLUMwMGZSNUVlei1qSjN1dTFDWHdKUTJ0eFp6SUV2SU9WbkpGbWRUZXpfMGxuYkVpMHZaNDctMnp4NzE5RkxfTHc?oc=5","date":"2026-03-06","type":"pipeline","source":"pharmaphorum","summary":"Day One's big bet on tovorafenib just keeps paying off - pharmaphorum","headline":"Day One's big bet on tovorafenib just keeps paying off","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNbGhEQVhjTnk1SURmTk1MV1NreEpjS0QzejVFdkdWYno0aXZjOFZBc2VKTjNsQ0RhT05jazhMaXlTekZkbk0tdmd1dlNtUWtDYk5LUFVwUmlEZkFLZVFJa1ozdUcyRE1xeGhXTG1tc3NOSVZPRnVDc0VEWHlYbW0wY2FGSzcwOUxtUl9WSHdaLV94V0x6dV9wY1p2dG8zYXpEU2lqbG41Nl83OXJp?oc=5","date":"2026-03-06","type":"regulatory","source":"The Business Journals","summary":"How a Bay Area company won a drug approval and a $2.5 billion buyout in eight years - San Francisco Business Times - The Business Journals","headline":"How a Bay Area company won a drug approval and a $2.5 billion buyout in eight years - San Francisco Business Times","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBxVmYzQlJwMnhjeEw2cHZGTk1Sb2JlcV9KU1FZcVVlR3RuMEcweFVjZmhlRG9FcUF4cFA2bVFHQzYxel8yLWw5dnRDRnVoX1hKbXZyQmFBdnZnbnBNSGJIMw?oc=5","date":"2025-08-05","type":"pipeline","source":"ACS Publications","summary":"No drug left behind - ACS Publications","headline":"No drug left behind","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPX2QweWVoLU1qYXFyeG1jN2RLdER4RVdCSHAyVWR3VXZjVnhsZmRENG1RWGVVTWRWcnZFbmp0SE9lVnJSbUpjS2hWcGFVX1lpY1A4RXlFcXVlRWlfUXFVd0tRX3BjbHFfYkNreFNtVGJMdVRZUEZHelZCWFNqaW9UMHZlbk4?oc=5","date":"2024-05-28","type":"pipeline","source":"pharmaphorum","summary":"Ex-Jazz, Sunesis exec Swisher takes over at NodThera - pharmaphorum","headline":"Ex-Jazz, Sunesis exec Swisher takes over at NodThera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBoME1zZ1FveTZjR09CWHlWakhaYVZmUy1rWXgzN2RwOW5sMExBZjlGSVZfSkFGR1UzZXE1ZlMxTUZJbmkybDltVVl6RVlaYlU5OVJaMDFESjZibEJxSGxn?oc=5","date":"2024-05-02","type":"trial","source":"Nature","summary":"Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison - Nature","headline":"Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxObGF5NlZKUE9NdHpzUDFQWm5jc0o1TmU5NzJzbVlkM2dIOVdxSTkwTGoyS1VHX3RSSHNlNGNsX2ZEMkhqRC1jVGtWMHdmNE4ySExPTi16RndzcHpxUUo4bEM0Q2NIeGlCNWk3Y29rMTJDNzd6TFNXSzV6Tk5fcVF5OTN0U19ldmhNT09YUVRFQmszY3F2Sm14c3hzdm53dlNhTWhCQkJOcjdfMVhHb3VTZEVvc09tb2M3TGxwVjBpcWpnWVhaZHYzdzBSSkx6X2xoaEJMSE1wZTJKTXluYm10cGp3R25kU1NaZk1PNldtZHk?oc=5","date":"2021-02-25","type":"deal","source":"prnewswire.com","summary":"Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement - prnewswire.com","headline":"Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZDUyb2VEMnZ1anA0RjBVaDNUUS1yWDF5RW0wVkEyU0F0cldPSFUwRlVGVWZGWVZDU05kSEtzYjl1SGxXbHF2NWJJOTZpV3lkMDg2RjVmdUdxWXdScVh5REp1Vk1CV2ltUGJHXzEwOWZqOFRaZ1g4WS1JV21zOGpudWU1Ylp0VFF4bXhCSkM5Y1pjNnhG?oc=5","date":"2021-02-23","type":"pipeline","source":"InvestorPlace","summary":"SNSS Stock: Why Sunesis Pharmaceuticals Is Soaring Today - InvestorPlace","headline":"SNSS Stock: Why Sunesis Pharmaceuticals Is Soaring Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQakllc3RtaEM3eHlZal9VRkVNUjB3c21rWi1BUDJrdlR3ZC05dDZxRU9mSG51MlhObElCMkdLaVNLYXNBZWdyV2dnSThKZTdRRnZMZWJIZFRsaGJOaDFLZlBJUHhuM2hIRkNENHRqNndTZ2Y1XzVLd3VGRk1Iekt1SUhBVnVSSnUwRVQ1ZmpMM25DM0NUSi1NWlNBVm5Kdi1MazEteG03aVE5VlRxeFpVRUhONkFpVU5XSlhLWmh2RkU0d19ET2ZZVmRLMEZfV0RFODl5LXE1MDB5TW1rdVhBTVVOYnNXVXpVcjNpd3ltaVlreEk?oc=5","date":"2020-11-30","type":"deal","source":"GlobeNewswire","summary":"Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement - GlobeNewswire","headline":"Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPblk2ck1JY29NS3lpUXhaQ1QyT3dSLURJZU1lRXJQVDBwSHBvYmtBd2FCWDRheV9fNFNwamlXWWxjZ0pmbnRuQWpNU2luZzhjckt4aUFpWjJQYUhuVXlXdWg2R0xQYWpDQzhsTTRpMzRNeTBuNU9PcUFmNmRxX3ZPZmVHYW12Y0cyUnJ0YlNFRkhmZ1A3RzRWUE5TWUVFYmhu?oc=5","date":"2019-07-01","type":"pipeline","source":"Fortune Business Insights","summary":"Chronic lymphocytic leukemia Market Size, Share, Forecast to 2034 - Fortune Business Insights","headline":"Chronic lymphocytic leukemia Market Size, Share, Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5qYzFyVm1XclNQem41bXM0ZF9jRzJ3MGhWcmxIVV9SM2dTa2d5N0RTbFhuQmJ0LWlWVjRvS0dsYXkxZWhicHVsb2V2S0lUYUhOQ0d3bkgtMjU?oc=5","date":"2018-09-22","type":"pipeline","source":"ASCO Publications","summary":"Treatment of Acute Promyelocytic Leukemia With No or Minimal Chemotherapy: Now a Reality in Common Clinical Practice - ASCO Publications","headline":"Treatment of Acute Promyelocytic Leukemia With No or Minimal Chemotherapy: Now a Reality in Common Clinical Practice","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxNcl84LTh2d0RJQ1loRm83a3p1d1VwdGxSMFZ0VENuWUpPR05meTJRbkFUWGg1N25pZFlLb2hPemZjdEFpWkdoMUFBRW9BVC1zU3VXdGh4cG9BNjQxWU1NM3F0el9QbzRjUGgwQ1Y1MVQ1LUVaYlU4dmFzeFpmdTljaHNkdXBBTkFScGZVUWJqeENBQm50eG5JY0dKRzdYNDlJRVBXSg?oc=5","date":"2017-05-02","type":"pipeline","source":"Fierce Biotech","summary":"Sunesis slumps after pulling plug on leukemia drug vosaroxin in Europe - Fierce Biotech","headline":"Sunesis slumps after pulling plug on leukemia drug vosaroxin in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE1uN2R3LUxyenhPQjZqc0RvTmZEaVNwNmQ3dzB2UHBzVmx1NEs0RjRUcHhXcWxHZk9VcnN0NHF2MWlLRFFZY3BFTXVWa244VUNzZjZXakJubW9CU2stSHFWTVZMcTlhYTZJZ1hqUXplZG9EQQ?oc=5","date":"2014-11-28","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"30 Top VC Firms for Biotechs - Genetic Engineering and Biotechnology News","headline":"30 Top VC Firms for Biotechs","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}